Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299548 | 1.00 | LMNA (0.65) | LMNANPSR1SMN1; SMN2ALOX12HPGD | |
| SCHEMBL4305747 | 0.79 | MAPT (0.52) | LMNASMN1; SMN2ALOX12HPGDMAPT | |
| SCHEMBL15250703 | 0.79 | MAPT (0.52) | LMNASMN1; SMN2ALOX12HPGDMAPT | |
| SCHEMBL4305748 | 0.79 | MAPT (0.52) | LMNASMN1; SMN2ALOX12HPGDMAPT | |
| SCHEMBL16274228 | 0.74 | SMN1; SMN2 (0.48) | LMNANPSR1SMN1; SMN2ALOX12THRB | |
| SCHEMBL16274230 | 0.74 | SMN1; SMN2 (0.48) | LMNANPSR1SMN1; SMN2ALOX12THRB | |
| SCHEMBL3822985 | 0.73 | HPGD (0.80) | LMNANPSR1SMN1; SMN2ALOX12HPGD | |
| SCHEMBL31388324 | 0.73 | HPGD (0.80) | LMNANPSR1SMN1; SMN2ALOX12HPGD | |
| SCHEMBL26154061 | 0.70 | LMNA (0.61) | LMNANPSR1SMN1; SMN2ALOX12HPGD | |
| SCHEMBL31339240 | 0.69 | SMN1; SMN2 (0.62) | LMNANPSR1SMN1; SMN2ALOX12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1640361-B9 | ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST | SUMITOMO CHEMICAL CO (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-1640361-B1 | ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST | SUMITOMO CHEMICAL CO (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-7632970-B2 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1640361-A2 | ASYMMETRIC UREA COMPOUND AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUND BY ASYMMETRIC CONJUGATE ADDITION REACTION WITH THE SAME AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | RAD18, UTP18, UBE2G2 | LMNA 4526/4885NPSR1 3126/4885SMN1; SMN2 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.